About Pharvaris
Pharvaris is a company based in Leiden (Netherlands) founded in 2015 by Berndt Modig.. Pharvaris has raised $164.21 million across 3 funding rounds from investors including General Atlantic, Idinvest Partners and Kurma Partners. The company has 108 employees as of December 31, 2024. Pharvaris offers products and services including Deucrictibant. Pharvaris operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Leiden, Netherlands
- Employees 108 as on 31 Dec, 2024
- Founders Berndt Modig
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pharvaris N.V.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-145.19 M-33.13as on Dec 31, 2024
-
EBITDA
$-157.3 M-50.53as on Dec 31, 2024
-
Total Equity Funding
$164.21 M (USD)
in 3 rounds
-
Latest Funding Round
$80 M (USD), Series C
Nov 18, 2020
-
Investors
General Atlantic
& 8 more
-
Employee Count
108
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pharvaris
Pharvaris is a publicly listed company on the NASDAQ with ticker symbol PHVS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pharvaris
Pharvaris offers a comprehensive portfolio of products and services, including Deucrictibant. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medication for preventing and treating HAE attacks effectively
Unlock access to complete
Unlock access to complete
Leadership Team
16 people
Software Development Team
5 people
Product Management Team
4 people
Human Resources and Administration
3 people
Finance and Accounting
3 people
Head Team
2 people
Sales and Marketing
2 people
Data Analysis and Operations Team
2 people
Unlock access to complete
Funding Insights of Pharvaris
Pharvaris has successfully raised a total of $164.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $80.0M
-
First Round
First Round
(01 Jun 2015)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Series C - Pharvaris | Valuation | Viking Capital , General Atlantic | |
| Sep, 2019 | Amount | Series B - Pharvaris | Valuation | Foresite Capital | |
| Jun, 2015 | Amount | Series A - Pharvaris | Valuation | Kurma Partners , Life Sciences Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pharvaris
Pharvaris has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include General Atlantic, Idinvest Partners and Kurma Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Private equity fund focused on global markets
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pharvaris
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pharvaris
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pharvaris Comparisons
Competitors of Pharvaris
Pharvaris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
B cells are programmed as biofactories for therapeutic protein delivery.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pharvaris
Frequently Asked Questions about Pharvaris
When was Pharvaris founded?
Pharvaris was founded in 2015.
Where is Pharvaris located?
Pharvaris is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Who is the current CEO of Pharvaris?
Berndt Modig is the current CEO of Pharvaris. They have also founded this company.
Is Pharvaris a funded company?
Pharvaris is a funded company, having raised a total of $164.21M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18.21M, raised on Jun 01, 2015.
How many employees does Pharvaris have?
As of Dec 31, 2024, the latest employee count at Pharvaris is 108.
What does Pharvaris do?
Pharvaris was founded in 2015 and is based in Leiden, Netherlands. As a preclinical-stage biopharmaceutical company, focus is placed on developing oral therapies for hereditary angioedema. The lead candidate, PHA121, functions as a bradykinin B2 receptor competitive antagonist and has shown activity in relevant disease models. Advancement of this molecule into IND-enabling studies is underway. Operations center on bradykinin-mediated conditions within the rare disease sector.
Who are the top competitors of Pharvaris?
Pharvaris's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
What products or services does Pharvaris offer?
Pharvaris offers Deucrictibant.
Is Pharvaris publicly traded?
Yes, Pharvaris is publicly traded on NASDAQ under the ticker symbol PHVS.
Who are Pharvaris's investors?
Pharvaris has 9 investors. Key investors include General Atlantic, Idinvest Partners, Kurma Partners, Life Sciences Partners, and Viking Capital.
What is Pharvaris's ticker symbol?
The ticker symbol of Pharvaris is PHVS on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.